1. Cellectis Release: Four Prominent Physicians To Join Clinical Advisory Board

    Cellectis Release: Four Prominent Physicians To Join Clinical Advisory Board

    Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells, today announced that four new members joined Cellectis’ Clinical Advisory Board (CAB). The CAB serves as a strategic resource to Cellectis as the Company enters the clinical development of allogeneic CAR T immunotherapies lead by its wholly owned product candidate, UCART123...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Quotes

    1. We are honored that these leaders have agreed to join Cellectis' Clinical Advisory Board as forward-thinking experts, innovators and visionaries in their respective fields.
    2. As Cellectis is expected to start the world's first clinical trial to ever use an allogeneic CAR T therapy in the U.S., the Company's Clinical Advisory Board will greatly guide us in moving full steam ahead.
  3. Topics Mentioned